203 related articles for article (PubMed ID: 27367163)
1. Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients.
Boutin M; Lavoie P; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.23.1-17.23.9. PubMed ID: 27367163
[TBL] [Abstract][Full Text] [Related]
2. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
3. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
4. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
5. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
6. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.
Dupont FO; Gagnon R; Boutin M; Auray-Blais C
Curr Med Chem; 2013; 20(2):280-8. PubMed ID: 23092136
[TBL] [Abstract][Full Text] [Related]
7. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
8. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.
Boutin M; Gagnon R; Lavoie P; Auray-Blais C
Clin Chim Acta; 2012 Dec; 414():273-80. PubMed ID: 23041216
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
Nowak A; Mechtler T; Kasper DC; Desnick RJ
Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
[TBL] [Abstract][Full Text] [Related]
11. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
12. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
13. Analysis of globotriaosylceramide (Gb
Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C
Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250
[TBL] [Abstract][Full Text] [Related]
14. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
15. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
17. Analysis of lyso-globotriaosylsphingosine in dried blood spots.
Johnson B; Mascher H; Mascher D; Legnini E; Hung CY; Dajnoki A; Chien YH; Maródi L; Hwu WL; Bodamer OA
Ann Lab Med; 2013 Jul; 33(4):274-8. PubMed ID: 23826564
[TBL] [Abstract][Full Text] [Related]
18. One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease.
Hong X; Gelb MH
Mol Genet Metab; 2018 Nov; 125(3):292-294. PubMed ID: 30126819
[TBL] [Abstract][Full Text] [Related]
19. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
20. Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease.
Ishii S; Taguchi A; Okino N; Ito M; Maruyama H
J Biol Chem; 2020 Apr; 295(17):5577-5587. PubMed ID: 32179651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]